Investigating DNA damage response in advanced endometrial cancer
Official title: Pathology Core
Funded at Dana-Farber Cancer Inst · NIH-11070326 · Data updated 2026-11-12
This study is looking at how advanced endometrial cancer reacts to certain types of damage at the DNA level, and it aims to find helpful markers in tissue samples that could lead to new treatments tailored for patients like you.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $531,886 |
| NIH project number | 5P01CA269021-02 |
| Project ID | NIH-11070326 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with advanced endometrial cancer, particularly those with specific genetic mutations such as TP53.
✕Less likely to help
Patients with early-stage endometrial cancer or those without the targeted genetic mutations may not benefit from this research.
What this research studies
This research focuses on understanding how advanced endometrial cancer responds to DNA damage and replication stress. Led by experts in pathology and biomarker development, the project aims to analyze human and mouse tissue samples to identify key biomarkers associated with treatment responses. Patients may benefit from innovative therapies targeting specific genetic mutations and pathways involved in their cancer. The research will also explore the potential of enhancing anti-tumor immunity through novel treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for women with advanced endometrial cancer.
How similar studies have gone: Previous research has shown promise in targeting DNA damage responses in cancer, indicating potential for success with similar approaches in this study.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Shapiro, Geoffrey I — Dana-Farber Cancer Inst
- Study coordinator: Shapiro, Geoffrey I
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.